Marfan Sartan: a randomized, double-blind, placebo-controlled trial.
about
A Case Based Approach to Clinical Genetics of Thoracic Aortic Aneurysm/Dissection.Marfan syndrome: current perspectivesLong-term miR-29b suppression reduces aneurysm formation in a Marfan mouse model.The Genetics of Aortopathies in Clinical Cardiology.The effect of losartan therapy on ventricular function in Marfan patients with haploinsufficient or dominant negative FBN1 mutationsThe year in cardiology 2015: peripheral circulation.Variable severity of cardiovascular phenotypes in patients with an early-onset form of Marfan syndrome harboring FBN1 mutations in exons 24-32.Marfan Syndrome and Related Disorders: 25 Years of Gene Discovery.Vascular smooth muscle cells in Marfan syndrome aneurysm: the broken bricks in the aortic wall.Sudden death due to aortic pathology.Aetiology and management of hereditary aortopathy.The spectrum of spontaneous coronary artery dissection: illustrated review of the literature.Aortic events in a nationwide Marfan syndrome cohort.Resveratrol Inhibits Aortic Root Dilatation in the Fbn1C1039G/+ Marfan Mouse ModelTherapeutics Targeting Drivers of Thoracic Aortic Aneurysms and Acute Aortic Dissections: Insights from Predisposing Genes and Mouse Models.NT-proBNP and diastolic left ventricular function in patients with Marfan syndrome.Strategies to prevent aortic complications in Marfan syndrome.Association between malignancies and Marfan syndrome: a population-based, nested case-control study in Taiwan.AP-1 Oligodeoxynucleotides Reduce Aortic Elastolysis in a Murine Model of Marfan Syndrome.Beta-blockers for preventing aortic dissection in Marfan syndrome.Crossing Bridges between Extra- and Intra-Cellular Events in Thoracic Aortic Aneurysms.The Effect of a Non-peptide Angiotensin II type 2 receptor Agonist, Compound 21, on Aortic Aneurysm Growth in a Mouse Model of Marfan Syndrome.An iPSC-derived vascular model of Marfan syndrome identifies key mediators of smooth muscle cell death.Efficacy of losartan as add-on therapy to prevent aortic growth and ventricular dysfunction in patients with Marfan syndrome: a randomized, double-blind clinical trial.Marfan and Sartans: time to wake up!2017 ESC/EACTS Guidelines for the management of valvular heart disease.Atherosclerosis, neoatherosclerosis, and vascular disease.Deregulated microRNA and mRNA expression profiles in the peripheral blood of patients with Marfan syndrome.Angiotensin, transforming growth factor β and aortic dilatation in Marfan syndrome: Of mice and humans.High prevalence of ventricular repolarization abnormalities in people carrying TGFβR2 mutations
P2860
Q26744537-6920147A-89E7-4452-8D88-9CE945551EC8Q26747739-172E3056-9C25-47D0-B8D2-120CD0E977F0Q33612367-AAFC7E98-A4A2-44E2-BBAE-E243D89CC074Q33758342-BBA03F55-C452-489D-B4B7-98F3139AD039Q37341800-F86140FA-407C-4E1F-B78E-EBA1E6A06B76Q38685687-0C1B8742-5DBD-4AB5-8C2A-322954453F02Q38706381-EA63FA40-A177-4988-9A7D-684A8E9E828AQ38751533-A621B0CE-07FD-456F-9FB3-60BA5EBCFA5FQ38930482-CE0C3ABA-48F8-40DF-8B0E-9104B0D2926CQ39085595-9DB66286-141F-4549-8162-7F6CCD763824Q39094762-16EFB85C-8E0C-4ECE-8504-0D66CD200445Q39402194-5112E045-166E-44EF-857A-CDF4B58B1B12Q39464795-3260A950-5A7D-4B9A-9CF6-875416F627C4Q39694748-7E3B0035-6843-49EA-B404-48DF103CBDB5Q40952704-BD0EE37C-AAB3-48F6-8B11-91CC8670AD8BQ42230262-29986E7A-73C8-4523-A7AC-23F823B78706Q42341364-86931DE3-0795-47A2-81CA-5E5E9091097BQ42650213-012BB711-B256-4854-BD3A-860FE2860E82Q47104189-02B9E0D2-DA18-4ABA-8D90-860AFBFF494EQ47645094-BCCBA9D4-28F7-4D68-9C01-36728E85A79CQ47751472-EC81CE48-67B2-41FF-A9B2-55DEEB38D563Q47752010-9308149B-4D95-4877-8C6C-50A700CF0FCFQ48194218-FC610A1A-673E-4C46-9814-E1A6BDC541E6Q49083618-FD273EDA-10EB-4425-AA85-DAFB503C9205Q49134981-5A777370-065F-4B04-B90A-5713AD12EFCAQ50196541-DE09256F-7827-4A9E-BB2F-762CACA22B97Q51799316-521A7384-19DC-4938-981F-8EFEAB1E32D4Q54940461-B0A0BC18-AC95-4DCB-9D3D-91F849D71EA6Q55266983-E7270E61-92E7-46AF-AB68-623F927956A6Q57244819-AEC02721-E82F-46C0-B80D-9BF03CF8F021
P2860
Marfan Sartan: a randomized, double-blind, placebo-controlled trial.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Marfan Sartan: a randomized, double-blind, placebo-controlled trial.
@en
Marfan Sartan: a randomized, double-blind, placebo-controlled trial.
@nl
type
label
Marfan Sartan: a randomized, double-blind, placebo-controlled trial.
@en
Marfan Sartan: a randomized, double-blind, placebo-controlled trial.
@nl
prefLabel
Marfan Sartan: a randomized, double-blind, placebo-controlled trial.
@en
Marfan Sartan: a randomized, double-blind, placebo-controlled trial.
@nl
P2093
P2860
P50
P356
P1476
Marfan Sartan: a randomized, double-blind, placebo-controlled trial.
@en
P2093
Adeline Basquin
David Attias
Delphine Detaint
Florence Arnoult
Florence Tubach
Francois Sassolas
Gabriel Delorme
Guillaume Jondeau
Henry Plauchu
Jean-Eric Wolf
P2860
P304
P356
10.1093/EURHEARTJ/EHV151
P577
2015-05-02T00:00:00Z